We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDCO
176
PUT
DELISTED
Medicines Co
MDCO
$523K 0.03%
+184
New +$6.09K
TCRT icon
177
Alaunos Therapeutics
TCRT
$4.64M
$506K 0.03%
+737
New +$494K
CATX icon
178
Perspective Therapeutics
CATX
$327M
$496K 0.03%
22,538
-39,615
-64% -$403K
PRTA icon
179
PUT
Prothena Corp
PRTA
$448M
$479K 0.03%
+125
New +$4.03K
AGEN
180
CALL
Agenus
AGEN
$275M
$477K 0.03%
77
+62
+413% +$4.31K
LUMO
181
PUT
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$472K 0.03%
+18
New +$5.5K
MNTA
182
PUT
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$445K 0.02%
382
+250
+189% +$4.23K
EXEL icon
183
PUT
Exelixis
EXEL
$14.2B
$430K 0.02%
1,216
+867
+248% +$5.9K
TSRO
184
CALL
DELISTED
TESARO, Inc.
TSRO
$413K 0.02%
+140
New +$4.41K
ENTA icon
185
CALL
Enanta Pharmaceuticals
ENTA
$367M
$408K 0.02%
+102
New +$3.71K
NWBO
186
CALL
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$399K 0.02%
551
+433
+367% +$2.57K
DMK
187
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$386K 0.02%
868
-4,947
-85% -$2.24M
ACHN
188
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
$376K 0.02%
1,142
-349
-23% -$1.22K
ECYT
189
CALL
DELISTED
Endocyte, Inc. Common Stock
ECYT
$367K 0.02%
154
+47
+44% +$681
GLMD icon
190
Galmed Pharmaceuticals
GLMD
$4.41M
$360K 0.02%
+174
New +$408K
RXII
191
CALL
DELISTED
GALENA BIOPHARMA INC COM
RXII
$350K 0.02%
1,400
-30
-2% -$7.5K
ATHX
192
PUT
DELISTED
Athersys, Inc. Common Stock
ATHX
$339K 0.02%
42
+23
+121% +$2.13K
HZNP
193
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$331K 0.02%
219
+108
+97% +$1.22K
PGNX
194
CALL
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$324K 0.02%
+794
New +$4.06K
TCRT icon
195
CALL
Alaunos Therapeutics
TCRT
$4.64M
$316K 0.02%
5
-12
-71% -$8.04K
ADXS
196
PUT
DELISTED
Advaxis Inc
ADXS
$314K 0.02%
+67
New +$4.73K
SEEL
197
PUT
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
WINT
198
CALL
DELISTED
Windtree Therapeutics Inc
WINT
$304K 0.02%
101
+94
+1,343% +$3.16K
IMUC
199
PUT
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$293K 0.02%
60
-33
-35% -$1.61K
OREX
200
DELISTED
Orexigen Therapeutics, Inc.
OREX
$291K 0.02%
+4,478
New +$303K
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.